Aceijas Carmen, Hickman Matthew, Donoghoe Martin C, Burrows Dave, Stuikyte Raminta
Centre for Research on Drugs and Health Behaviour (CRDHB), London School of Hygiene and Tropical Medicine (LSHTM), Department of Public Health and Policy, London, UK.
Addiction. 2007 Aug;102(8):1244-50. doi: 10.1111/j.1360-0443.2007.01848.x. Epub 2007 Jun 12.
To estimate access, activity and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia.
Two data sets ('regional' and 'high-coverage sites') were used to estimate NSP provision (availability/number of sites), NSP utilization (syringes distributed/year), needle and syringe distribution (needles/syringes distributed/IDU/year), IDU reached (number/percentage of IDU contacted/year), regular reach (five or more contacts/month) and syringe coverage (percentage of injections/IDU/year administrable with new injecting equipment).
Regional data set: results from 213 sites in 25 countries suggested that Czech Republic, Poland, Russia and Ukraine had > 10 NSP during 2001/2. Czech Republic, Kazakhstan, Latvia, Russia, Slovakia and Ukraine had >or= 10,000 IDU in contact with NSP. Ten countries reached >or= 10% of the estimated IDU population. The 25 countries distributed approximately 17 million syringes/needles. Eight countries distributed > 0.5 million syringes/year. Syringe coverage (assuming 400 injections/IDU/year) was < 5% in 19 countries, 5-15% in five and > 15% in Macedonia. Overall syringe coverage was 1.2% and when assuming 700 injections/IDU/year it decreased to 0.7%. Syringe coverage for the IDU population in contact with NSP was <or= 15% in 10 countries, 15-60% in 11 and > 60% in Croatia, Macedonia, Moldova and Tajikistan. Overall syringe coverage for the population in contact with NSP was 9.8%. High-coverage data set: Soligorsk, Pskov and Sumy's NSP reached 92.3%, 92.2% and 73.3% of their estimated IDU population, respectively (regular reach: 0.2%, 1.8% and 22.7%). The distribution levels were 47.2, 51.7 and 94.2 syringes/IDU/year, respectively.
The evidence suggests suboptimal levels of NSP implementation, programme activity and coverage. This paper provides a baseline for development of indicators that could be used to monitor NSP. Strategies to increase coverage that may go beyond NSP are urgently required, as is research into understanding how NSP can contribute to better syringe coverage among IDU.
评估中东欧和中亚地区针头和注射器项目(NSP)的可及性、活动情况及覆盖范围。
使用两个数据集(“区域”和“高覆盖点”)来评估NSP的提供情况(可及性/站点数量)、NSP的使用情况(每年分发的注射器数量)、针头和注射器分发情况(每年每个注射吸毒者分发的针头/注射器数量)、覆盖的注射吸毒者数量(每年接触到的注射吸毒者数量/百分比)、定期覆盖情况(每月接触五次或更多次)以及注射器覆盖范围(每年可使用新注射设备进行注射的注射吸毒者的百分比)。
区域数据集:来自25个国家213个站点的结果表明,捷克共和国、波兰、俄罗斯和乌克兰在2001/2年期间有超过10个NSP。捷克共和国、哈萨克斯坦、拉脱维亚、俄罗斯、斯洛伐克和乌克兰有超过或等于10000名注射吸毒者与NSP有接触。10个国家覆盖了估计注射吸毒者人口的10%或更多。这25个国家每年分发约1700万支注射器/针头。8个国家每年分发超过50万支注射器。注射器覆盖范围(假设每个注射吸毒者每年注射400次)在19个国家低于5%,5个国家为5 - 15%,马其顿超过15%。总体注射器覆盖范围为1.2%,若假设每个注射吸毒者每年注射700次,则降至0.7%。与NSP有接触的注射吸毒者群体的注射器覆盖范围在10个国家低于或等于15%,11个国家为15 - 60%,克罗地亚、马其顿、摩尔多瓦和塔吉克斯坦超过60%。与NSP有接触的人群的总体注射器覆盖范围为9.8%。高覆盖数据集:索利戈尔斯克、普斯科夫和苏梅的NSP分别覆盖了其估计注射吸毒者人口的92.3%、92.2%和73.3%(定期覆盖情况:0.2%、1.8%和22.7%)。分发水平分别为每年每个注射吸毒者47.2、51.7和94.2支注射器。
证据表明NSP的实施、项目活动和覆盖范围未达到最佳水平。本文为制定可用于监测NSP的指标提供了基线。迫切需要采取超越NSP的提高覆盖范围的策略以及研究如何使NSP能为提高注射吸毒者中的注射器覆盖范围做出贡献。